Related Experiment Videos
New doxorubicin nanocarriers based on cyclodextrins
Maurizio Viale1, Valentina Giglio2, Massimiliano Monticone3
1IRCCS A.O.U. San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, U.O.C. Bioterapie, L.go R. Benzi 10, 16132, Genoa, Italy. maurizio.viale@hsanmartino.it.
Investigational New Drugs
|April 6, 2017
Summary
Functionalized nanoparticle-loaded fibrin gels (FBGs) show promise for localized cancer therapy. The oCyDNH2/DOXO complex within FBGs demonstrated controlled drug release and potent anti-cancer activity in vitro.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Drug Delivery
Background:
- Polymeric nanoparticles and fibrin gels (FBGs) are established platforms for localized delivery of biotherapeutics.
- Combining these approaches can enhance drug delivery characteristics and therapeutic efficacy.
Purpose of the Study:
- To develop and characterize nanoparticle-loaded FBGs for improved localized cancer therapy.
- To evaluate the drug release kinetics and in vitro anti-cancer activity of doxorubicin (DOXO)-loaded nanocarriers within FBGs.
Main Methods:
- Preparation of inclusion complexes of DOXO with functionalized oligomeric β-cyclodextrins (oCyD).
- Incorporation of these nanocarriers into FBGs.
- Assessment of DOXO release rates from FBGs.
- Evaluation of in vitro antiproliferative and apoptotic activities of the nanoparticle-FBG complexes.
Main Results:
- Nanocarrier/FBG complexes exhibited a decreased DOXO release rate compared to non-functionalized counterparts.
- The oCyDNH2/DOXO complex within FBGs showed significant in vitro antiproliferative and apoptotic activity.
- Enhanced cellular drug uptake was observed for the oCyDNH2/DOXO complex.
Conclusions:
- Functionalized nanocarriers, specifically oCyDNH2/DOXO complexes, can be effectively incorporated into FBGs to modulate drug release.
- These enhanced FBGs hold potential for localized anticancer therapy, particularly for inoperable or surgically removable tumors.